News and Press Releases
Clinical Trials | Researcher Resources | Cystic Fibrosis Foundation Therapeutics (CFFT) Drug Company Ends Ataluren Program for CF Nonsense Mutations

PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations. 

March 3, 2017 | 3 min read